WO2008140782A3 - Composés d'inhibition enzymatique - Google Patents

Composés d'inhibition enzymatique Download PDF

Info

Publication number
WO2008140782A3
WO2008140782A3 PCT/US2008/005997 US2008005997W WO2008140782A3 WO 2008140782 A3 WO2008140782 A3 WO 2008140782A3 US 2008005997 W US2008005997 W US 2008005997W WO 2008140782 A3 WO2008140782 A3 WO 2008140782A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
based compounds
compounds
enzyme inhibition
proteasome
Prior art date
Application number
PCT/US2008/005997
Other languages
English (en)
Other versions
WO2008140782A2 (fr
Inventor
Han-Jie Zhou
Guy J Laidig
Kevin D Shenk
Congcong M Sun
Original Assignee
Proteolix Inc
Han-Jie Zhou
Guy J Laidig
Kevin D Shenk
Congcong M Sun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteolix Inc, Han-Jie Zhou, Guy J Laidig, Kevin D Shenk, Congcong M Sun filed Critical Proteolix Inc
Publication of WO2008140782A2 publication Critical patent/WO2008140782A2/fr
Publication of WO2008140782A3 publication Critical patent/WO2008140782A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des composés à base de peptides comprenant des noyaux à trois chaînons contenant des hétéroatomes, qui inhibent de manière efficace et sélective des activités spécifiques de N-terminal nucléophile (Ntn) hydrolases associées au protéasome. Ces composés à base de peptides comprennent un époxide ou une aziridine, et une fonctionnalisation à l'extrémité N. Entre autres applications thérapeutiques, les composés à base de peptides peuvent présenter des propriétés anti-inflammatoires et d'inhibition de la prolifération cellulaire. L'administration par voie orale de ces inhibiteurs de protéasome à base de peptides est possible en raison de leur profil de biodisponibilité.
PCT/US2008/005997 2007-05-10 2008-05-09 Composés d'inhibition enzymatique WO2008140782A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92875807P 2007-05-10 2007-05-10
US60/928,758 2007-05-10

Publications (2)

Publication Number Publication Date
WO2008140782A2 WO2008140782A2 (fr) 2008-11-20
WO2008140782A3 true WO2008140782A3 (fr) 2008-12-31

Family

ID=39743821

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/005997 WO2008140782A2 (fr) 2007-05-10 2008-05-09 Composés d'inhibition enzymatique

Country Status (1)

Country Link
WO (1) WO2008140782A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102174076A (zh) 2004-04-15 2011-09-07 普罗特奥里克斯公司 用于抑制蛋白酶体酶的化合物
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
DK2030981T3 (da) 2004-05-10 2014-10-13 Onyx Therapeutics Inc Forbindelser til proteasom-enzymhæmning
PL1948678T3 (pl) 2005-11-09 2013-09-30 Onyx Therapeutics Inc Związki do hamowania enzymów
DK2041158T3 (da) 2006-06-19 2013-06-24 Onyx Therapeutics Inc Peptid-epoxidketoner til proteasom inhibering
KR20150131405A (ko) 2007-10-04 2015-11-24 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
EP2349313A4 (fr) 2008-10-21 2012-08-29 Onyx Therapeutics Inc Thérapie de combinaison avec des peptides époxycétones
AP2912A (en) * 2009-03-20 2014-05-31 Onyx Therapeutics Inc Crystalline tripeptide epoxy protease inhibitors
AU2013203857B2 (en) * 2009-03-20 2016-05-19 Onyx Therapeutics, Inc. Crystalline tripeptide epoxy ketone protease inhibitors
AR075899A1 (es) * 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
MX2012010017A (es) 2010-03-01 2012-10-01 Onyx Therapeutics Inc Compuestos de para la inhibicion de inmunoproteasomas.
DK3702374T3 (da) 2012-02-15 2022-06-27 Cydex Pharmaceuticals Inc Fremsgangsmåde til fremstilling for cyclodextrin-derivater
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
CN109096370B (zh) * 2012-07-26 2022-03-18 圣特莱国际公司 多肽环氧酮化合物
CA2888822C (fr) 2012-10-22 2021-01-26 Cydex Pharmaceuticals, Inc. Compositions de cyclodextrine alkylee et procedes de preparation et d'utilisation de celles-ci
TW201422255A (zh) 2012-10-24 2014-06-16 Onyx Therapeutics Inc 用於蛋白酶體抑制劑之調整釋放製劑
KR102360356B1 (ko) 2014-07-14 2022-02-08 센트랙스 인터내셔널, 아이엔씨. 효소 억제를 위한 에폭시케톤 화합물
WO2016029179A1 (fr) 2014-08-22 2016-02-25 Cydex Pharmaceuticals, Inc. Compositions de cyclodextrine alkylée fractionnées et leurs procédés de préparation et d'utilisation
CN105949279A (zh) * 2016-04-27 2016-09-21 浙江大学 蛋白酶体抑制剂Oprozomib及其类似物的制备方法
CN110092813B (zh) * 2019-06-05 2021-05-11 南京师范大学 一种三肽环氧丙烷衍生物及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111008A2 (fr) * 2004-05-10 2005-11-24 Proteolix, Inc. Composes d'inhibition enzymatique
WO2006045066A2 (fr) * 2004-10-20 2006-04-27 Proteolix, Inc. Composes pour inhibition d'enzymes
WO2007056464A1 (fr) * 2005-11-09 2007-05-18 Proteolix, Inc. Composés pour l'inhibition d'enzymes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111008A2 (fr) * 2004-05-10 2005-11-24 Proteolix, Inc. Composes d'inhibition enzymatique
WO2006045066A2 (fr) * 2004-10-20 2006-04-27 Proteolix, Inc. Composes pour inhibition d'enzymes
WO2007056464A1 (fr) * 2005-11-09 2007-05-18 Proteolix, Inc. Composés pour l'inhibition d'enzymes

Also Published As

Publication number Publication date
WO2008140782A2 (fr) 2008-11-20

Similar Documents

Publication Publication Date Title
WO2008140782A3 (fr) Composés d'inhibition enzymatique
MY145757A (en) Compounds for enzyme inhibition
WO2005111008A3 (fr) Composes d'inhibition enzymatique
HK1231491A1 (zh) 用於抑制蛋白酶體的化合物
WO2005105827A3 (fr) Composes pour l'inhibition enzymatique
CL2012000738A1 (es) Compuestos heterociclicos derivados de indol, inhibidores de xantina-oxidasa; composición farmacéutica que los comprende; procedimiento de preparación; y uso en el tratamiento de enfermedades tales como hiperuricemia, gota, insuficiencia cardiaca, hipertensión, diabetes, hiperlipidemia, obesidad, aterosclerosis, entre otras.
CR9962A (es) Compuestos para inhibicion enzimatica

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08767663

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08767663

Country of ref document: EP

Kind code of ref document: A2